ProStrakan Group Plc expects to break even in 2009 on the back of continued revenue growth for its four marketed products and the expected US launch in the second half of 2008 of Sancuso, a treatment to prevent the side effects of chemotherapy. ---Subscribe to MedNous to access this article--- Company News
